RT Journal Article
SR Electronic
T1 877 Intermittent dosing of the ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib promotes antitumor immunity by remodelling the tumor immune microenvironment in pre-clinical models
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A977
OP A977
DO 10.1136/jitc-2023-SITC2023.0877
VO 11
IS Suppl 1
A1 Hardaker, Elizabeth
A1 Karmokar, Ankur
A1 Milo, Marta
A1 Michaloglou, Chrysiis
A1 Hughes, Adina
A1 King, Matthew
A1 Solanki, Anisha
A1 Magiera, Lukasz
A1 Miragaia, Ricardo
A1 Kar, Gozde
A1 Peter, Alison
A1 Talbot, Sara
A1 Lam, Carolyn
A1 Sutton, Daniel
A1 Hoffmann, Scott
A1 Carnevalli, Larissa
A1 Wilson, Zena
A1 Fawell, Stephen
A1 Cobbold, Mark
A1 Valge-Archer, Viia
A1 Gabrilovich, Dmitry
A1 Lau, Alan
A1 Barry, Simon
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A977.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.